Cubist Systematic Strategies LLC Raises Stock Position in Delcath Systems, Inc. (NASDAQ:DCTH)

Cubist Systematic Strategies LLC grew its stake in shares of Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) by 43.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 117,404 shares of the company's stock after acquiring an additional 35,394 shares during the period. Cubist Systematic Strategies LLC owned about 0.37% of Delcath Systems worth $1,414,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of DCTH. Jane Street Group LLC bought a new position in Delcath Systems in the third quarter worth about $110,000. Barclays PLC bought a new stake in Delcath Systems in the third quarter worth $104,000. Baader Bank Aktiengesellschaft acquired a new position in Delcath Systems during the 4th quarter worth $204,000. Principal Financial Group Inc. lifted its position in Delcath Systems by 28.8% during the 4th quarter. Principal Financial Group Inc. now owns 115,183 shares of the company's stock worth $1,387,000 after acquiring an additional 25,736 shares during the last quarter. Finally, Private Advisor Group LLC bought a new stake in Delcath Systems in the fourth quarter valued at about $153,000. 61.12% of the stock is currently owned by institutional investors and hedge funds.

Delcath Systems Trading Up 6.5%

NASDAQ DCTH traded up $1.05 on Friday, hitting $17.10. 538,582 shares of the company were exchanged, compared to its average volume of 367,128. The stock has a fifty day moving average of $12.61 and a 200-day moving average of $12.77. Delcath Systems, Inc. has a 12 month low of $6.33 and a 12 month high of $17.15. The company has a market cap of $595.52 million, a PE ratio of -12.67 and a beta of 0.72.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.07). Delcath Systems had a negative return on equity of 338.16% and a negative net margin of 150.70%. The business had revenue of $19.80 million for the quarter, compared to the consensus estimate of $16.83 million. On average, analysts expect that Delcath Systems, Inc. will post -0.79 earnings per share for the current year.

Analyst Ratings Changes

Separately, HC Wainwright increased their price target on shares of Delcath Systems from $22.00 to $24.00 and gave the company a "buy" rating in a research note on Friday, March 7th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Delcath Systems has an average rating of "Moderate Buy" and an average target price of $22.75.

Delcath Systems Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.